Evaxion Biotech A/S expected to post a loss of 31 cents a share - Earnings Preview

Evaxion A/S

29/10/2024 13:48

* Evaxion Biotech A/S  EVAX.OQ   EVAX.O  is expected to show
a
rise in quarterly revenue when it reports  results on October 31
for the period ending September 30 2024
    * The Copenhagen Denmark-based   company is expected to
report
revenue of $123.33 thousand, according to the mean estimate from
3 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Evaxion Biotech A/S is
for a
loss of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evaxion
Biotech
A/S is $8.00​, above​ its last closing price of $2.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.36       -0.39      -0.12     Beat    69.2
 Mar. 31 0001  -0.50       -0.55      0.30      Beat    154.1
 Dec. 31 2023  -1.60       -1.60      -1.60     Met     0​
 Sep. 30 2023              -1.95      -2.10     Missed  -7.7
 ​​Jun.        -2.15       -2.15      -2.10     Beat    2.3
 30 2023                                                
 Mar. 31 2023  -2.43       -2.40      -2.40     Met     0​
 Dec. 31 2022              -2.63      -2.90     Missed  -10.1
 Sep. 30 2022  -2.64       -2.67      -2.40     Beat    10
 This summary was machine generated October 29 at 13:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)